ddn Online

The Blog of Drug Discovery News

On the move…

I briefly considered some “I have a dream…”-style post musing about something and glomming onto the theme of MLK Day, then decided the Rev. Martin Luther King Jr. has been in his grave a short enough period that he might roll over, roll out, and clonk me on the head for sheer impertinence (and I’d deserve it). So, as some of us work today, and some of us don’t, but most of us try to remember how short a time ago (historically speaking) it was that civil rights in the United States was a painful joke and keep moving beyond that era, I’ll just keep it simple with a pair of “People & Promotion”-style items that go right to the top.

Xhale Innovations Inc.
Craig T. Davenport
Chief Executive Officer
GAINESVILLE, Fla.—With more than 35 years of experience in the healthcare industry and “a proven track record of leading, building, managing and investing in rapidly growing medical device technology companies,” Craig Davenport has been announced as the new CEO of Xhale Innovations Inc. Recently, he he had served as chairman, president and CEO of Endocare and, over six years, built the company into a leading provider of minimally invasive technologies to treat prostate, kidney, lung and other cancers using cryotherapy. Earlier in his career, he was chief operating officer and president of Tokos Medical Corp. when it was an early stage medical device manufacturer and clinical services provider, and over nine years he spearheaded the company’s growth from a handful of people to more than 3,000 employees, took the company public in 1990 and grew revenues from $3.7 million to more than $120 million.

Crescendo Biologics
Mike Romanos
Chief Executive Officer
CAMBRIDGE, U.K.—Crescendo Biologics has announced the appointment of Dr. Mike Romanos as CEO after having served as chief scientific officer of the company since May 2009, a position in which he led the formation of the company and the development of its proprietary antibody fragment technologies. During this time, Crescendo notes, the company has made significant progress in the establishment of its team and its technology platforms. This has included the establishment of a colony of engineered mice completely devoid of endogenous antibody polypeptides, announced in September. The proprietary ‘triple knockout’ mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion. Romanos brings more than 23 years’ biotech and pharma industry experience and within the last 10 years has held senior global positions leading major parts of GlaxoSmithKline Discovery.


January 17, 2011 - Posted by | Corporate, Promotions and Moves

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: